Consejo Superior de Investigaciones Científicas posted this:New treatment for epidermolysis bullosa and fibrosisCSIC, Carlos III University of Madrid and CIEMAT have repositioned drugs that stimulate endogline expression and modulate the TGF-β route for a new clinical use in the treatment of fibrosis, such as epidermolysis bullosa (EB). EB includes a heterogeneous group of rare hereditary diseases of the skin in which in its infantile incidence the patients are known as "butterfly children". It is a new therapy for a rare pathology, with potential in a wide spectrum of fibrosis, which would improve the possibilities of treatment of patients, improving their quality of life. Industrial partners from the pharmaceutical industry are being sought for its development in a wide variety of fibrotic pathologies through a patent licence agreement. An offer for Patent Licensing
Consejo Superior de Investigaciones Científicas posted this:Control of neurodegenerative diseases with benzothiazole-benzamide derivativesCSIC has developed a group of heterocyclic compounds derived from a privileged structural nucleus with the capacity to inhibit the LRRK2 enzyme. This inhibitory activity makes them useful in the treatment of neurodegenerative diseases affected by this enzyme, among which Parkinson's disease and Alzheimer's disease stand out. Pharmaceutical companies interested in the development and commercialization of these compounds under a patent license are sought. An offer for Patent Licensing
Consejo Superior de Investigaciones Científicas posted this:Compounds for the treatment of optic neuritisCSIC and the University of Athens have found that secoiridoids, such as oleacein and oleocanthal, are useful to prevent or treat neuropathies that conduct to optic nerve injury, such as optic neuritis. A company dealing with pharmaceutical or nutraceutical compositions for ophtalmic applications is sought for licensing agreement. An offer for Patent Licensing
Consejo Superior de Investigaciones Científicas posted this:Peptide for cancer control linked to IL13RCSIC has developed a peptide capable of inhibiting the signaling of IL-13 mediated by IL13Rα2. This peptide alone or within a nanoparticle or virus-like particles can be used in a pharmaceutical composition for the treatment of pathologies in which IL13Rα2 is overexpressed. This composition would be useful in the treatment and control of metastasis of colon cancer and other tumors (i.e glioblastoma), as well as in other pathologies such as asthma, atopic dermatitis or fibrosis. Industrial partners are being sought to develop and commercialized the products through a patent licence agreement. An offer for Patent Licensing
Consejo Superior de Investigaciones Científicas posted this:Regulatory compounds of synaptic transmission for the treatment of neurological diseasesThe CSIC and IRYCIS (Ramón y Cajal Institute for Health Research) have developed a group of compounds. These compounds have the ability to regulate the number of synapses that are formed between neurons, as well as the probability that neurotransmitters are released from these, because they have the capability of modulate the interactions that take place between the regulatory proteins NCS-1 and Ric8a that regulate these two independent processes. Due to these neuromodulatory properties, these compounds are useful for the treatment of neurological diseases as Alzheimer's disease, Huntington or Parkinson's diseases among others. Industrial partners from the ophthalmic or pharmaceutical industry are being sought to collaborate through a patent license agreement. An offer for Patent Licensing
uacoopera posted this:
Licensing Manager at uacoopera
Mª Eugenia Garcés Castellote posted this:
Commercialization Specialist at Universidad de Alcalá-OTRI
Centre Technology Transfer CITTRU posted this:Method of isolation and purification of xanthophylls from diatom cultureXanthophylls, with their antioxidant, anticancer, anti-inflammatory and neuroprotective properties, found important applications in food and nutrition, cosmetic and environmental industries, as well as pharmacy and medicine. Diadinoxanthin (Ddx) and diatoxanthin (Dtx) are two pigments that belong to xanthophylls family. The availability of Ddx and Dtx on the market is low and up to date limited as they are sold exclusively in small quantities at extremely high prices to be used as HPLC calibration standards. The solution of the above mentioned problems is the 5-step method for the isolation and purification of Ddx and Dtx developed at the Jagiellonian University..
Universidad de Alcalá-OTRI posted this:Protein separation by using anionic carbosilane dendrimers.BIODEN research group (Biomedical applications of dendrimers) from the Department of Inorganic Chemistry of the University of Alcala along with the research group of Micro(sep) from the Department of Analytical Chemistry and Chemical Engineering have developed a technology based on the use of anionic dendrimers as nanoadditives in capillary electrophoresis (CE) for protein separation, more specifically for obtaining protein profiles useful in food characterization. The groups look for companies of chemical, pharmaceutical or biotechnological sector to sign research collaboration agreements or license agreements.
Centre Technology Transfer CITTRU posted this:New method for efficient isolation of microbial DNA from bloodThe method of the invention is a solution that allows the simultaneous isolation of microbial DNA from the blood. In this method the isolation is carried out by compilation of enzymatic, mechanical and thermal lysis. This approach enables to obtain DNA from all types of organisms, irrespective of the structure of the cells.The obtained precipitate is subjected to further preparations, using a commercial DNA isolation kit according to the protocol provided by the manufacturer's procedure. The procedure results in obtaining the DNA ready for further stages of the analysis, e.g. performing a PCR reaction to detect fungi. The most important and most difficult problem in the treatment of bloodstream infections, determining the effectiveness of therapy and, consequently, the cost and time of hospitalization, is the effective diagnosis of factors responsible for the systemic inflammatory response in the course of sepsis. Determination of etiologic factors allows for selection of appropriate antibiotic therapy. The material subjected to diagnostic testing is blood taken from the patient showing clinical signs of sepsis. Currently, the "gold standard" diagnostic method is testing for microbial growth after inoculation in culture media specific to selected pathogen groups. This method is relatively simple and inexpensive, but also time-consuming – results can be available as late as in 5 days. Moreover, identification of pathogens with this method often fails due to low sensitivity; microbial growth can be detected in only about 15-20% of the cultures.
uacoopera posted this:
Licensing Manager at uacoopera